Abstract
Quantitative detection of human cytomegalovirus (HCMV) DNA on whole blood is currently the primary choice for virological monitoring in transplant patients and for determining the appropriate antiviral strategy, however specific issues of variability remain in terms of extraction methods, amplification efficiency, and variability. This study compared the performance characteristics of two nucleic acid extraction and testing systems for HCMV-DNA quantitation, the artus® CMV QS-RGQ kit, associated with a fully automated DNA extraction and assay set up by Qiagen (system 1) and the Q-CMV Real Time Complete kit by Nanogen, associated with a semiautomated nucleic acid extraction system by Biomérieux (system 2) in 189 specimens from transplant patients and 10 from 2012 HCMV Quality Control for Molecular Diagnostics (QCMD). The two systems exhibited a 80.4% concordance. Differences between the two systems were within ±1 log 10 copies/ml of the averaged log 10 results for 88.9% of the tested specimens. For all qualitatively discordant specimens, mean viral load was ≤3 log 10 copies/ml. Considering viral load measurement, system 1 gave earlier positives that system 2, with a 14.8% of specimens resulted positive at low viral loads with system 1 and negative with system 2. In QCMD specimens, difference was below 0.7 log10 copies/ml for both the systems.
In conclusion, the two systems provided reliable and comparable results. Some specific performance characteristic and automation could be taken into account in terms of less hands of time, fewer errors and reliability. in fact, HCMV-DNA quantitation provides sensitive and specific data for viral detection as well as monitoring the development and course of infection, thus being fundamental for determining the appropriate antiviral strategy. A relevant issue in HCMV routine diagnostics is the interassay quantitation variability (Hirsch et al., 2013; Lilleri et al., 2009) , possibly complicating the clinical management and therapeutic decision process in patients evaluated in different laboratories.
Recently, the first World Health organization international standard for HCMV quantitative nucleic acid amplification-based assays has been made available (Freyer et al., 2010) . Although the availability of the international standard should contribute to improve interassay agreement, specific issues of variability remain in terms of extraction methods and DNA elution, amplification efficiency, and operator-dependent variability (Hirsch et al., 2013; Kraft et al., 2012) . 
Materials and methods

Clinical specimens
One-hundred-fifty-six patients referred to the Virology Unit of the Azienda Ospedaliera Città della Salute e della Scienza di Torino, Italy, for routine HCMV load testing (90 solid organ transplant recipients and 66 hematopoietic stem cell transplant recipients) were included in the study. Onehundred-eighty-nine specimens of whole blood (EDTA tubes) were collected between January and June 2012. Ten HCMV quality control specimens (Quality Control for Molecular Diagnostics -QCMD-2012 CMV panel) were also processed.
Study design
Two nucleic acid extraction and testing systems for HCMV-DNA were evaluated: the artus® CMV QS-RGQ kit (Qiagen), a commercial real-time PCR for HCMV-DNA associated with a fully automated DNA extraction from whole blood (Qiasymphony, Qiagen) and automated assay set upsystem 1 -and the Q-CMV Real Time Complete kit, a commercial real-time PCR (Nanogen, Elitech Group) associated with a semiautomated nucleic acid extraction system from whole blood (Easymag, Biomérieux) and manual assay set up -system 2. Currently, the Q-CMV Real Time Complete kit, validated for EasyMAG extraction system by the manufacturer, is the routinely used method.
For system 1, nucleic acid extraction was performed according to the manufacturer's instructions;
nucleic acid was purified with the QIAsymphony DNA Mini kit on the QIAsymphony instrument (Qiagen). Two-hundred microliters of whole blood were concentrated into a 60-µl eluate, and a 20 μl aliquot was used for the PCR on the real-time PCR cycler Rotor-Gene Q (Qiagen). The artus® CMV QS-RGQ kit targets the major immediate early (MIE) CMV gene. The reaction volume was 50-µl (20 µl of eluate plus 30 µl of master mix). Analytical sensitivity, as reported by the manufacturer, considering purification from whole blood (using the QIAsymphony DNA Mini kit) and the use of artus® CMV QS-RGQ kit on the Rotor-Gene Q, is 164.55 copies/ml. For system 2, nucleic acid was purified with the NucliSENS® EasyMAG® instrument (Biomérieux), using the NucliSENS ® Nucleic Acid Extraction Reagents, according to the manufacturer's instructions.
One-hundred microliters of whole blood were concentrated into a 50-µl eluate, and a 5µl aliquot was used for PCR assay on the 7500 Real-Time PCR System (Applied Biosystems, Cheshire, United Kingdom). The Q-CMV Real Time Complete kit manufactured for Cepheid by Nanogen Advanced Diagnostics S.r.L. is specific for the exon 4 region of the CMV MIE gene (major immediate early HCMVUL123). The reaction volume was 25 µl (5 µl of eluate plus 20 µl of master mix). The limit of detection of the Q-CMV real time kit is 158 copies/ml, as reported by the manufacturer. The main technical features of the two systems are summarized in Table 1 .
Statistical analysis
The correlation between the two systems was determined by linear regression analysis and mean differences in quantitation for averaged logs by the Bland-Altman plot. Only viral loads positive by both assays were represented on the Bland-Altman graphs. Differences were considered significant for p value <0.05.
Discussion
The automation of nucleic acid extraction and availability of commercial real-time quantitative PCR assays have the potential to improve the agreement and clinical usefulness of HCMV-DNA measurement in routine transplant settings, thus promoting standardization across laboratories and enabling correlation with clinical study results.
In the present study, the HCMV -DNA load results obtained by two nucleic acid extraction and testing systems have been compared. Overall, both systems appear as reliable and user-friendly for monitoring HCMV-DNAemia in transplant recipients.
The two systems exhibited an overall concordance of 80.4% in qualitative terms. Considering specimens that were positive by both the systems, the mean viral load differs of 0.19 log 10 copies/ml. On the other hand, when considering specimens that were qualitatively discordant, mean viral load was lower or equal to 3 log 10 copies/ml.
Considering viral load measurement, system 1 gave earlier positives that system 2, as evidenced by the evaluation of frequency distribution for different log of viral load (not shown), with approximately 15% of specimens resulted positive at low viral loads with system 1 and negative with system 2. This is likely to be attributable to the fact that system 1 employs more blood derived material in comparison to system 2, thus improving the recovery ability in the nucleic acid purification phase. This should be taken into account in the monitoring of transplant recipients as it could be useful for prompt identification of patients at risk and could allow for rechecking on a subsequent specimen within a short period.
Monitoring of HCMV-DNAemia has become critical for early identification of viral reactivation
with the aim of reducing the occurrence of systemic and/or organ disease in the post-transplant setting and of evaluating the response to antiviral therapy. Although both antiviral prophylaxis and pre-emptive therapy are useful strategies to prevent the occurrence of HCMV disease, the potential exposure to adverse events associated with prolonged antiviral drug administration has limited the utility of a universal prophylaxis strategy, thus suggesting its adoption only in high risk patients, such as HCMV-seropositive donor/HCMV-seronegative recipients. On the other hand, viral load monitoring for guiding pre-emptive therapy is critical. The adoption of a pre-emptive strategy appears advantageous in terms of number of treated patients, appropriateness of antiviral administration and duration of therapy, costs, risks of onset of drug adverse events, as well as emergence of drug-resistant strains.
By using the Bland-Altman analysis, differences between the two systems were within ± 1 log 10 copies/ml of the averaged log 10 results for almost 89% of the tested specimens. The occurrence of constant and variable quantitation differences among nucleic acid assays underlines the usefulness of a general quantitative standardization, that could also allow for a better evaluation of specific differences only related to different technical performances of the assays.
From an organizational point of view, system 1, being a full-automated system, provides benefits over a semi-automated system, in terms of less hands of time, fewer errors and reliability, that are relevant factors in a high-routine laboratory. It is to note that the present study compared two testing systems with two different extraction methods, therefore it is not known whether the differences came from the nucleic acid purification techniques or from the two HCMV tests or probably both; further studies including cross-test of both extraction methods with both PCR systems could help to clarify this. Further data on a larger number of specimens and evaluation of clinical management based on HCMV-DNAemia results will allow for better definition of the performance characteristics and clinical validation.
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